drugset / Trial / NCT03892928

Safety and Efficacy of Dexmedetomidine in Painless Colonoscopy

NCT03892928 ↗

Completed 104 enrolled West China Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

104 patients who undergo painless colonoscopy from Decemenber 1,2019 to June 30,2022 will be randomized to two groups: propofol group and dexmedetomidine group. In the dexmedetomidine group,dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. In the propofol group, Propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 during the whole process.

Timeline

Start
2019-12-01
Primary completion
2022-06-30
Completion
2022-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.3 ug/kg Intravenous

Indications

No indication recorded.